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Chlamydia trachomatis is an obligate intracellular bacterium that has
developed sophisticated mechanisms to survive inside its infectious compartment,
the inclusion. Notably, Chlamydia weaves an extensive network of microtubules
(MTs) and actin ﬁlaments to enable interactions with host organelles and enhance
its stability. Despite the global health and economic burden caused by this sexually
transmitted pathogen, little is known about how actin and MT scaffolds are integrated into an increasingly complex virulence system. Previously, we established
that the chlamydial effector InaC interacts with ARF1 to stabilize MTs. We now
demonstrate that InaC regulates RhoA to control actin scaffolds. InaC relies on
cross talk between ARF1 and RhoA to coordinate MTs and actin, where the presence of RhoA downregulates stable MT scaffolds and ARF1 activation inhibits actin
scaffolds. Understanding how Chlamydia hijacks complex networks will help elucidate how this clinically signiﬁcant pathogen parasitizes its host and reveal novel
cellular signaling pathways.

IMPORTANCE Chlamydia trachomatis is a major cause of human disease worldwide.
The ability of Chlamydia to establish infection and cause disease depends on the
maintenance of its parasitic niche, called the inclusion. To accomplish this feat,
Chlamydia reorganizes host actin and microtubules around the inclusion membrane.
How Chlamydia orchestrates these complex processes, however, is largely unknown.
Here, we discovered that the chlamydial effector InaC activates Ras homolog family
member A (RhoA) to control the formation of actin scaffolds around the inclusion, an
event that is critical for inclusion stability. Furthermore, InaC directs the kinetics of
actin and posttranslationally modiﬁed microtubule scaffolds by mediating cross talk
between the GTPases that control these cytoskeletal elements, RhoA and ADP-ribosylation factor 1 (ARF1). The precise timing of these events is essential for the maintenance of the inclusion. Overall, this study provides the ﬁrst evidence of ARF1-RhoAmediated cross talk by a bacterial pathogen to coopt the host cytoskeleton.
KEYWORDS ARF1, Chlamydia, GTPases, RhoA, actin, cytoskeleton, microtubules

A

ctin and tubulin are among the most abundant proteins in eukaryotic cells and
are involved in essential cellular processes, including organelle positioning and
function. Together, they comprise the most critical components in the cytoskeleton:
actin ﬁlaments and microtubules (MTs). Additional cellular proteins regulate each
cytoskeletal element’s structure, dynamics, and function and, consequently, the fundamental biological processes dependent on the cytoskeleton (1). As a result, these regulatory components of the cytoskeleton are signiﬁcant targets for intracellular bacterial
pathogens (2–4).
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Chlamydia trachomatis is the most common cause of bacterial sexually transmitted
disease. It is also the most frequent cause of infectious blindness, known as trachoma
(5). C. trachomatis displays a unique biphasic lifestyle. The infectious form, called the elementary body (EB), exhibits minimal metabolic activity and promotes its entry into
human epithelial cells. Once inside the host cell, Chlamydia EBs reside within a membrane-bound compartment called the inclusion. EBs then rapidly differentiate into a
replicative form, called the reticulate body (RB), which is metabolically active and noninfectious. As RBs replicate by binary ﬁssion, they synthesize effector proteins that
remodel and hijack the host cell to promote their survival (6). In doing so, Chlamydia
subverts many aspects of the host cellular environment, including the host cytoskeleton, a critical element of successful infection and dissemination of C. trachomatis within
the host.
EBs initially invade the host cell by attaching to the plasma membrane and injecting
the chlamydial protein Tarp (translocated actin recruiting protein) into the host cytoplasm via the chlamydial type III secretion system. Phosphorylation of Tarp in the cytosol allows Tarp to recruit the guanine nucleotide exchange factors (GEFs) Sos1 and
Vav2, which activate Rac1 (7). Tarp directly binds actin monomers to nucleate new linear ﬁlaments (8, 9). Subsequently, the Arp2/3 complex is activated, and branched actin
ﬁlaments are polymerized underneath the bacterial binding site to promote the entry
of the EBs into the nascent inclusion (10–12).
The second wave of cytoskeletal manipulation begins around 16 h postinfection
(hpi), when MTs are assembled around the inclusion (13). These scaffolds are subsequently stabilized and undergo posttranslational modiﬁcation (PTM), including detyrosination and acetylation (14, 15). PTMs inﬂuence MT structure and depolymerization
rates, further increasing their stability (16, 17). We have previously established that the
small GTPase ARF1 controls the posttranslational modiﬁcation of MT scaffolds. PTM-MT
scaffolds then position Golgi ministacks around the inclusion, which provides lipids to
facilitate the rapid expansion of the inclusion (14, 15, 18). Around 32 hpi, actin scaffolds
form around the inclusion. These structures physically reinforce the inclusion membrane to prevent premature lysis, as the inclusion expands to occupy most of the host
cytoplasm (19). Using actin-depolymerizing agents and small interfering RNA (siRNA),
the formation of F-actin at the inclusion was shown to be RhoA dependent (19).
Finally, Chlamydia exits its host cell either by controlled cell lysis or through extrusion, which also relies on the intervention of the host cytoskeleton. Extrusion is a nonlytic process during which the inclusion protrudes out of the infected cell before pinching off the plasma membrane (20). This event requires the mobilization of RhoA,
WASP, and myosin II. Interestingly, MT depolymerization with nocodazole does not
affect extrusion, suggesting this event is actin speciﬁc (20).
Interference with the host cytoskeleton dramatically impacts the outcome of
Chlamydia infection. The inhibition of PTM-MT scaffolds decreases Chlamydia infectivity, whereas their enhancement increases it, demonstrating the importance of this
cytoskeletal element in Chlamydia development (14). Global inhibition of actin polymerization with latrunculin also causes early rupture of inclusions, indicating that actin
is essential for maintaining inclusion stability (19). Inclusion stability solely depends on
actin, as MT depolymerization does not impact inclusion integrity (19).
Previous work investigating Chlamydia has been signiﬁcantly limited by its reliance
on cytoskeleton-modulating drugs. These drugs disrupt the host cytoskeleton in its entirety and often indirectly impact other cytoskeletal elements (21). As a result, elucidating the precise local role of actin and MT scaffolds during Chlamydia infection has
been challenging. However, with advances in Chlamydia genetics, targeted disruption
of Chlamydia’s virulence system and its effector proteins is now possible without indirectly affecting native host processes. Recently, we and others showed that a single
chlamydial effector, InaC (also called CT813 or CTL0184), controls the formation of the
kinetically and functionally distinct actin and PTM-MT scaffolds (15, 19, 22). InaC knockout (KO) Chlamydia produces less-infectious progeny and generates smaller inclusions,
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RESULTS
RhoA activation is required for the formation of actin scaffolds around the
inclusion. To understand the exact role of RhoA during C. trachomatis infection and to
assess whether RhoA is the sole regulator of actin scaffold formation, we generated
CRISPR/Cas9 RhoA KO HeLa cells (see Fig. S1A in the supplemental material). HeLa cells
transfected with the Cas9 vector without guide RNA were used as a control. RhoA KO
cells also express similar amounts of actin, a-tubulin, and acetylated a-tubulin compared to control cells (Fig. S1B). We detected a modest but statistically insigniﬁcant
increase in detyrosinated a-tubulin in the absence of RhoA. As expected, RhoA KO cells
are viable and divide similarly to control cells (Fig. S1C and D).
Next, we assessed the kinetics of actin scaffold formation in the presence and absence of RhoA during Chlamydia infection. Control and RhoA KO cells were infected
with wild-type (WT) C. trachomatis L2 prior to the analysis of actin scaffolds around the
inclusion at different times postinfection. In parallel, RhoA KO cells were transfected
with a vector encoding myc-RhoAWT (RhoAWT) at 3 to 4 hpi to restore RhoA expression.
In control cells, actin scaffolds are detected at 38 hpi, but not 24 hpi (Fig. 1A and B,
Control), consistent with previous observations that actin scaffolds form late during
infection (19). In contrast, actin scaffolds were not detectable at either time point in
RhoA KO cells (Fig. 1A and B, RhoA KO). The expression of myc-RhoAWT rescued the
loss of actin scaffolds in RhoA KO cells at 38 hpi (Fig. 1B, RhoAWT), indicating that the
loss of actin scaffolds in RhoA KO cells is not due to an off-target effect of Cas9.
Like all small GTPases, RhoA cycles between GDP- and GTP-bound states, which in
turn control its interactions with downstream effectors (23). To assess whether
Chlamydia infection inﬂuences the activation state of RhoA to promote actin polymerization around the inclusion, we infected HeLa cells with C. trachomatis L2 and generated lysates from mid to late times postinfection (16 to 48 hpi). The levels of RhoA-GTP
were then analyzed using the RhoA-binding domain (RBD) of the effector Rhotekin
(24). The activation of RhoA reaches a maximal level at 32 hpi (Fig. 1C), which correlates with both the formation of actin scaffolds and the recruitment of endogenous
RhoA to the inclusion (Fig. S2). Note that RhoA activation is a transient event, as it is
deactivated and returns to noninfected levels at ;40 hpi. These data indicate that C.
trachomatis triggers the activation of RhoA at the same time that actin polymerization
occurs around the inclusion.
To establish the role of RhoA activation in the formation of actin scaffolds, we
exploited the well-characterized G14V (myc-RhoAG14V, GTP locked) and T19N (mycRhoAT19N, dominant negative) RhoA mutants, which have been used extensively to
explore the biological activities of RhoA (25–27). At 3 to 4 hpi with C. trachomatis L2,
we transfected RhoA KO cells with either myc-RhoAG14V or myc-RhoAT19N and compared
the formation of actin scaffolds to that of cells transfected with myc-RhoAWT. We found
that myc-RhoAG14V, but not myc-RhoAT19N, supports actin scaffold formation (Fig. 1D).
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indicating that InaC-dependent pathways are essential for Chlamydia ﬁtness (15, 19).
We also demonstrated that InaC directly interacts with the host small GTPases ARF1
and ARF4 to control the formation of PTM-MTs and, consequently, the dispersal of
Golgi ministacks around the inclusion during infection (15). This event occurs midcycle
at 16 to 24 hpi. In addition to InaC, it has been shown that actin scaffold formation
around 32 hpi is mainly dependent on the host GTPase RhoA (19). Whether InaC regulates RhoA and how both GTPases are coordinated during infection to generate their
speciﬁc scaffolds at the optimal time is unknown.
Here, we report that while RhoA can be recruited to the inclusion in the absence of
InaC, its activation, which leads to the formation of actin scaffolds, requires InaC.
Furthermore, we discovered that the presence of RhoA downregulates ARF1 activation,
while ARF1-GTP inhibits RhoA activation, highlighting cross talk between two small
GTPases to coordinate PTM-MT and actin scaffolds during infection. Overall, our ﬁndings establish that a single chlamydial effector, InaC, is a master regulator of actin and
MT dynamics during Chlamydia infection.

®

FIG 1 Active RhoA is required for the formation of actin scaffolds around the inclusion. (A and B) Control and RhoA KO cells were infected with WT C.
trachomatis L2 (MOI of 2) and transfected with empty or myc-RhoAWT DNA at 4 hpi. Cells were ﬁxed at 24 or 38 hpi and labeled with phalloidin to label
actin (red), anti-myc antibody to label RhoA (green), and anti-MOMP antibody to label individual Chlamydia (cyan). Asterisks denote inclusions. The white
box indicates the magniﬁed area shown to the right of the image (Zoom). Images are representative of 3 independent experiments. Scale bar, 25 m m. (C)
HeLa cells were infected with WT C. trachomatis L2 (MOI of 1) for the indicated times prior to lysis and isolation of RhoA-GTP using the RhoA binding
domain of Rhotekin immobilized on agarose beads. In the Western blot, RhoA-GTP denotes the RhoA signal from the pulldown, and Total RhoA represents
the amount of RhoA from the cell lysate. The graph indicates the fold increase in RhoA-GTP compared to a noninfected control (t = 0). Results are
representative of two independent experiments. (D) RhoA KO cells were infected with WT C. trachomatis L2 (MOI of 2) and transfected with myc-RhoAWT,
myc-RhoAG14V, or myc-RhoAT19N DNA at 4 hpi. Cells were ﬁxed 30 hpi and labeled with anti-myc (green) antibody and phalloidin (red). Scale bar, 20 m m.
Asterisks denote inclusions. The white box indicates the magniﬁed area shown to the right of the image (Zoom). The graph denotes the average
percentage of inclusions containing actin scaffolds from 3 independent experiments 6 the standard deviation. Data are normalized to myc-RhoAWTexpressing cells. A minimum of 100 inclusions was counted for each condition per experiment. ****, P , 0.0001.

Compared to infected myc-RhoAWT-expressing cells, the expression of myc-RhoAG14V
maximizes actin scaffold formation to 126% 6 3.7%. In comparison, only 9% 6 2.1% of
inclusions displayed actin scaffolds in RhoAT19N-expressing cells, demonstrating that
active RhoA is required to promote actin scaffold formation. Interestingly, actin scaffolds become detectable at 24 hpi in cells expressing constitutively active mycRhoAG14V, while they are absent in cells expressing myc-RhoAWT and myc-RhoAT19N (see
Fig. S3 in the supplemental material). In this case, we observe that 86% 6 4.2% of
inclusions have actin scaffolds as early as 24 hpi. This is not due to a shift in RhoA
recruitment since endogenous RhoA is already present on the inclusion at 24 hpi (Fig.
S2) despite the absence of actin scaffolds (Fig. 1A). Altogether, these data indicate that
the temporal activation of RhoA is critical and dictates the kinetics of actin scaffold formation during infection.
The chlamydial effector InaC is required for the activation of RhoA. InaC is a
chlamydial effector that is required for the formation of actin scaffolds during
November/December 2021 Volume 12 Issue 6 e02397-21
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Chlamydia infection (15, 19). To establish whether InaC regulates the activity of RhoA
during infection, we made use of a C. trachomatis L2 mutant in which the InaC gene
was inactivated using Targetron (InaC KO Chlamydia) (15). We then infected HeLa cells
with InaC KO C. trachomatis L2 and quantiﬁed the amount of RhoA-GTP at 32 hpi.
Infection with WT C. trachomatis L2 increased RhoA-GTP levels 2.9 6 0.54-fold compared to uninfected control cells (Fig. 2A). In contrast, InaC KO-infected cells exhibited
RhoA-GTP levels similar to control cells (0.983 6 0.34-fold change), indicating that InaC
is required in RhoA activation during C. trachomatis infection.
One way that proteins regulate each other is through direct interactions. We thus
tested whether InaC forms a complex with RhoA to control its activation locally. To do
so, we conducted a series of immunoprecipitation experiments in the presence and absence of infection in different conﬁgurations. However, we could not detect an interaction (see Fig. S4 in the supplemental material), indicating that either InaC and RhoA do
not bind or the interaction is too weak or transient to detect.
Even though InaC and RhoA do not form a detectable complex, the recruitment of
RhoA to the inclusion could still be indirectly impacted by the absence of InaC, which
would explain the reduction in RhoA-GTP in cells infected with InaC KO C. trachomatis
L2 (Fig. 2A). To assess whether RhoA recruitment to the inclusion depends on InaC, we
used RhoA KO cells complemented with myc-RhoAWT and infected with WT or InaC KO
C. trachomatis L2. At 32 to 38 hpi, infected cells were ﬁxed and stained with anti-myc
and anti-InaC antibodies to label RhoA and the inclusion membrane, respectively. As
expected, myc-RhoAWT was present on the inclusion membrane in WT C. trachomatis
L2-infected cells (Fig. 2B, WT L2). Interestingly, myc-RhoAWT was also detected on the
inclusion membrane of InaC KO C. trachomatis L2-infected cells (Fig. 2B, InaC KO), indicating that RhoA recruitment is InaC independent. Next, we assessed whether both
mutant forms of RhoA are differentially recruited during infection with InaC KO
Chlamydia. As shown in Fig. 2C and D, myc-RhoAG14V (Fig. 2C) and myc-RhoAT19N
(Fig. 2D) are also recruited to the inclusion in both WT and InaC KO C. trachomatis L2infected cells. These data further indicate that RhoA is recruited to the inclusion independently of its activation state.
We then determined whether the loss of actin scaffolds in InaC KO C. trachomatis
L2-infected cells is due to a defect in RhoA activation. To do so, we infected RhoA KO
HeLa cells with WT or InaC KO C. trachomatis L2, followed by transfection with mycRhoAWT, myc-RhoAG14V, or myc-RhoAT19N DNA. The cells were ﬁxed at 32 to 38 hpi and
labeled with anti-myc and anti-InaC antibodies. As observed earlier, myc-RhoAWT and
myc-RhoAG14V, but not myc-RhoAT19N, promote the formation of actin scaffolds during
WT C. trachomatis infection (Fig. 2B to E, WT L2). Strikingly, the expression of mycRhoAG14V, but not myc-RhoAWT or myc-RhoAT19N, rescues the InaC KO phenotype and
fully restores the formation of actin scaffolds (Fig. 2B to E, InaC KO), indicating that the
loss of actin scaffolds in InaC KO-infected cells is due to an inability to activate RhoA.
Altogether, these results demonstrate that InaC is not required to recruit RhoA but
rather to locally activate it and promote actin scaffold formation around the inclusion.
Since RhoA does not interact with InaC, it is likely that an additional host or bacterial
factor that remains to be identiﬁed is involved.
InaC-RhoA-mediated cytoskeletal scaffolds contribute to inclusion stability. InaC
is required for the formation of both PTM-MT and actin scaffolds (15, 22). However,
their direct contribution to inclusion stability is not well understood. To test the importance of these scaffolds in Chlamydia ﬁtness, we infected HeLa cells with InaC KO C. trachomatis L2 and assessed inclusion stability over time. In WT C. trachomatis L2-infected
cells, we observed that ;40% of inclusions were ruptured at 48 hpi. In contrast, ;50%
of the InaC KO inclusions were lysed by 32 hpi (Fig. 3A), indicating a substantial shift in
inclusion stability in the absence of InaC. This early release of Chlamydia into the cytosol correlated with a 2.4-fold increase in cell death measured by caspase 3/7 activation.
While only 5% 6 0.98% of WT C. trachomatis L2-infected cells were positive for caspase
3/7 activation, 12% 6 0.86% of InaC KO C. trachomatis L2-infected cells were positive
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FIG 2 The chlamydial effector InaC is required for the activation of RhoA. (A) HeLa cells were
infected with the indicated C. trachomatis L2 strains (MOI of 1) for 32 h. RhoA-GTP was isolated as
described in Fig. 1C. In the Western blot, anti-InaC antibody conﬁrms the loss of InaC in the InaC KO
strain and anti-MOMP antibody conﬁrms infection. The graph denotes the average fold change in
RhoA-GTP compared to the uninfected control 6 the standard deviation from 3 independent
experiments. **, P , 0.01; ns, not signiﬁcant. (B to D) RhoA KO cells were infected with WT or InaC
KO C. trachomatis L2 (MOI of 2) and transfected with myc-RhoAWT (B), myc-RhoAG14V (C), or mycRhoAT19N (D) DNA at 4 hpi. Cells were ﬁxed at 38 hpi and labeled with phalloidin (green), anti-myc

(Continued on next page)
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at 72 hpi (Fig. 3B). InaC KO inclusions were stabilized when InaC-FLAG was reintroduced on a plasmid (see Fig. S5A and C in the supplemental material). As expected,
the complementation of InaC expression also rescued the loss of actin scaffolds
(Fig. S5B). Overall, this indicates that InaC is critical for the maintenance of inclusion
stability.
To speciﬁcally test the impact of the loss of actin scaffolds on inclusion stability,
RhoA KO cells were infected with WT C. trachomatis L2, and inclusion lysis was measured at 72 hpi as it corresponds to maximal caspase 3/7 activation (Fig. 3B). As controls,
we infected RhoA KO cells with InaC KO C. trachomatis L2 and treated WT C. trachomatis L2-infected cells with latrunculin B to depolymerize all host cell actin. Consistent
with previous reports (19), latrunculin B treatment increased levels of inclusion lysis
[Fig. 3C, WT L2, (Lat)]. Compared to control cells, inclusion lysis increased by ;15% in
the absence of RhoA (Fig. 3C, Ctrl-WT L2 versus RhoA KO-WT L2). Control and RhoA KO
cells infected with InaC KO C. trachomatis L2 showed similar levels of inclusion lysis to
RhoA KO cells infected with WT C. trachomatis L2, indicating that InaC and RhoA function in the same pathway to control inclusion stability (Fig. 3C, Ctrl InaC KO versus
RhoA KO WT L2). These results suggest that actin scaffolds, but not PTM-MT scaffolds,
generated through an InaC-RhoA-dependent pathway speciﬁcally contribute to the
stability of inclusions during infection.
The presence of RhoA inhibits the formation of PTM-MT scaffolds during infection.
PTM-MT scaffolds around the inclusion are most evident around 24 hpi, whereas the
formation of actin scaffolds around the inclusion begins later, around 32 hpi (15, 19).
Furthermore, actin scaffolds do not form in the absence of RhoA, and PTM-MT scaffolds
are disorganized in the absence of ARF1. These data suggest that these two cytoskeletal
pathways are independent of each other and are controlled by their corresponding small
GTPase. This concept is supported by the fact that each GTPase is activated at speciﬁc
times during infection: 16 hpi for ARF1 (see Fig. S6 in the supplemental material) and 32
hpi for RhoA (Fig. 1C). Yet, the requirement for the chlamydial protein InaC to control
both cytoskeletal events indicates that some degree of cross talk likely exists between
these two pathways. Since the inclusion is a fundamental component of Chlamydia pathogenicity, this cross talk may allow InaC to ﬁnely control the activation/inactivation of
each pathway to appropriately time Golgi repositioning and inclusion stability. In this
case, we would expect that altering the expression level and/or activity level of either
GTPase would impact the formation of the other cytoskeletal element.
To test this hypothesis, we ﬁrst investigated the impact of RhoA depletion on the formation of PTM-MTs during infection. RhoA KO cells were infected with WT C. trachomatis
L2, and the PTM-MT scaffolds around the inclusion at 24 hpi were monitored using immunoﬂuorescence microscopy. As expected, PTM-MT scaffolds still assemble around the
inclusion in the absence of RhoA, demonstrating that RhoA is not required for their formation (Fig. 4A and B). However, we observe increases of 48% 6 8.8% and 28% 6 7.4%
of detyrosinated and acetylated a-tubulin scaffolds, respectively, compared to control
cells (Fig. 4A and B, graphs). This enhanced formation of PTM-MT scaffolds is suppressed
to WT levels when myc-RhoAWT is expressed in RhoA KO cells, conﬁrming that the phenotype is speciﬁcally due to the loss of RhoA (Fig. 4A and B, RhoAWT). Furthermore, the
expression of either active or inactive RhoA mutants in RhoA KO cells suppresses the
enhanced formation of PTM-MTs similarly to myc-RhoAWT (see Fig. S7 in the supplemental material). These results indicate that this phenomenon is due to the presence of
RhoA rather than a speciﬁc nucleotide-bound state. Altogether, these data suggest that
the absence of RhoA enhances the formation of PTM-MTs.
FIG 2 Legend (Continued)
antibody (red), and anti-InaC antibody (cyan). Asterisks denote inclusions. Scale bar, 20 m m. Results
are representative of at least 3 independent experiments. (E) The graph displays the average
percentage of inclusions with actin scaffolds 6 the standard deviation from 3 independent
experiments. Data are normalized to cells infected with WT C. trachomatis L2 and transfected with
myc-RhoAWT DNA. A minimum of 100 inclusions was counted for each condition per experiment.
***, P , 0.001; ****, P , 0.0001.
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FIG 3 InaC-mediated cytoskeletal pathways contribute to the stability of chlamydial inclusions. (A) HeLa cells were infected
with WT or InaC KO C. trachomatis L2 (MOI of 0.5) and ﬁxed at the indicated times postinfection. Cells were labeled with antiIncA antibody (green) to label the inclusion membrane and anti-MOMP antibody (red). Hoechst was used to label DNA (gray).
Asterisks denote intact inclusions. Scale bar, 10 m m. The adjacent graph represents the average percentage of broken
inclusions at the indicated time points from 3 independent experiments 6 the standard deviation. **, P , 0.01; ***, P ,
0.001. (B) Nuclight Red HeLa cells were infected with WT or InaC KO C. trachomatis L2 (MOI of 1) for 6 h before the addition
of IncuCyte caspase 3/7 green dye for apoptosis at a ﬁnal concentration of 5 m M. The cells were then imaged every 2 h until
72 hpi on an IncuCyte Zoom imaging system. Nuclei of HeLa cells are shown in red, and caspase 3/7 puncta are shown in
green. Scale bar, 300 m m. The graph depicts the average percentage of caspase 3/7-positive cells from 4 independent
experiments 6 the standard deviation. A minimum of 100 inclusions was counted for each condition. NI, not-infected cells. *,
P , 0.05; **, P , 0.01; ***, P , 0.001. (C) Control and RhoA KO HeLa cells were infected with WT or InaC KO C. trachomatis
L2 (MOI of 0.5) and ﬁxed at 72 hpi. As a control, one set of WT C. trachomatis L2-infected cells was treated with 0.5 m M
latrunculin B or ethanol (vehicle control) in cell culture medium for 30 min at 37°C 5 h prior to ﬁxation. Vehicle and
latrunculin B were washed out with cell culture medium, and the cells were ﬁxed at 72 hpi. Cells were labeled with anti-IncA
antibody (green) to label the inclusion membrane and Hoechst (gray) to stain DNA. Scale bar, 40 m m. Asterisks denote intact
inclusions. WT L2 (Lat), latrunculin B-treated cells. The graph depicts the average percentage of broken inclusions from 3
independent experiments 6 the standard deviation. A minimum of 100 inclusions was counted for each condition. *, P ,
0.05; **, P , 0.01; ***, P , 0.001.
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FIG 4 The formation of PTM-MT scaffolds during infection is enhanced in the absence of RhoA. (A and B)
Control and RhoA KO HeLa cells were infected with WT C. trachomatis L2 (MOI of 2) and transfected with
empty vector or myc-RhoAWT DNA at 4 hpi. Cells were ﬁxed at 24 hpi and labeled with anti-detyrosinated
a-tubulin (Dt a-tubulin) (A, green), anti-acetylated a-tubulin (Ac a-tubulin) (B, green), anti-myc (red), and
anti-MOMP (blue) antibodies. Scale bar, 30 m m. The graphs represent the average percentage of inclusions
with Dt a-tubulin (A) or Ac a-tubulin (B) scaffolds normalized to infected control HeLa cells. A minimum of
100 inclusions was counted for each condition per experiment. *, P , 0.05; **, P , 0.01; ***, P , 0.001;
ns, not signiﬁcant. (C) Control and RhoA KO HeLa cells were infected with InaC-FLAG-overexpressing C.
trachomatis L2 (MOI of 5) and treated with 5 ng/ml anhydrotetracycline (aTc) 4 hpi to induce InaC-FLAG
expression. Cells were lysed at 24 hpi, and InaC-FLAG was immunoprecipitated using an anti-FLAG
antibody. ARF1 binding was assessed with anti-ARF1 antibody. Lysates were analyzed as a control. AntiRhoA antibody conﬁrms the loss of RhoA in the RhoA KO. HSP70 served as a loading control. Results are
representative of 2 independent experiments. (D) Control and RhoA KO HeLa cells were infected with InaCFLAG-overexpressing C. trachomatis L2 (MOI of 5) and transfected with ARF1T31N-HA or ARF1Q71L-HA at 4
hpi. InaC-FLAG expression was induced with 5 ng/ml aTc 4 hpi. Cells were lysed at 24 hpi, and InaC-FLAG
was immunoprecipitated using anti-FLAG antibody. ARF1 binding was assessed with anti-HA antibody.
Lysates were analyzed as a control. Anti-RhoA antibody conﬁrms the loss of RhoA in the RhoA KO. HSP70
served as a loading control. Results are representative of 2 independent experiments.
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Since ARF1 is a critical factor in forming PTM-MT scaffolds (15), the enhancement of
PTM-MT scaffolds in the RhoA KO could be due to increased complex formation between
InaC and ARF1 and/or increased ARF1 activation. To test both possibilities, we infected
RhoA KO cells with C. trachomatis L2 expressing InaC-FLAG. We then assessed the interactions between InaC-FLAG and endogenous ARF1 compared to the complex formed in
control cells. As shown in Fig. 4C, we observe a striking increase in ARF1 binding to InaCFLAG in the absence of RhoA at 24 hpi. Next, we tested whether the enhanced interaction between ARF1 and InaC is with active or inactive ARF1. Control and RhoA KO cells
were transfected with either GDP-bound (ARF1T31N-HA [hemagglutinin]) or GTP-bound
(ARF1Q71L-HA) ARF1 (15, 28) at 3 to 4 hpi with C. trachomatis L2 expressing InaC-FLAG.
InaC was immunoprecipitated using an anti-FLAG antibody, and the immunoprecipitates
were analyzed by Western blotting to identify which ARF1 mutant was bound. As shown
in Fig. 4D, only ARF1Q71L-HA binds to InaC. The interaction with ARF1-Q71L and InaC is
enhanced in the absence of RhoA, demonstrating that the lack of RhoA results in an
increase in InaC:ARF1-GTP binding and consequently PTM-MT scaffold formation.
Activation of ARF1 impairs RhoA-GTP-dependent actin scaffold formation. The
recruitment of RhoA to the inclusion begins around 24 hpi (Fig. S2). During this time,
ARF1 is already activated, and PTM-MT scaffolds are forming. Since (i) the absence of
RhoA concomitantly leads to the loss of actin scaffolds and enhances the interaction
between ARF1-GTP and InaC (Fig. 4D) and (ii) ARF1 is not required for the formation of
actin scaffolds (see Fig. S8 in the supplemental material), we hypothesized that the
deactivation of ARF1 might be required for the subsequent downstream activation of
RhoA and the formation of actin scaffolds. To test this hypothesis, we expressed the
constitutively active ARF1Q71L-HA and dominant-negative ARF1T31N-HA mutants at 3 to
4 hpi with WT C. trachomatis L2 and assessed the formation of actin scaffolds at 32 hpi.
Interestingly, the constitutive activation of ARF1 drastically reduces actin scaffold formation by 45% (Fig. 5A and B, ARF1Q71L-HA). This effect is speciﬁc to the active form of
ARF1, as the expression of GDP-bound ARF1 does not inﬂuence actin scaffold formation (Fig. 5A and B, ARF1T31N-HA).
Next, we determined whether the constitutive activation of ARF1 blocks the activation
of RhoA. As shown in Fig. 5C, the activation of RhoA is inhibited by 68% 6 22% in cells
expressing ARF1Q71L-HA compared to cells transfected with ARF1WT-HA. Collectively, these
data demonstrate that cross talk between ARF1 and RhoA is critical for the coordination of
PTM-MT and actin scaffolds during C. trachomatis infection.
Together, our data support a model in which Chlamydia uses a single effector to
coordinate two small GTPases and regulate critical cytoskeletal pathways necessary for
its survival (Fig. 6). Speciﬁcally, ARF1 is activated midcycle (;16 hpi) in an InaC-dependent manner. At this time, RhoA is absent from the inclusion, leaving ARF1 activation unimpeded. As a result, ARF1-GTP actively drives the formation of PTM-MTs. In
turn, PTM-MT scaffolds coordinate Golgi rearrangement around the inclusion, which
contributes to inclusion growth (15). Around 24 hpi, RhoA starts to relocate to the
inclusion membrane. The presence of RhoA blocks ARF1 activation and the generation
of additional PTM-MTs. Simultaneously, ARF1-GTP inhibits actin scaffold formation by
interfering with RhoA activation. As the infection progresses, the concentration of
RhoA on the inclusion membrane increases, further inhibiting ARF1 activation. As ARF1
returns to its inactive GDP-bound state, it can no longer block RhoA activation. The
InaC-dependent activation of RhoA fully engages, peaking at 32 hpi and maximizing
actin polymerization around the inclusion. As a result, Chlamydia’s infectious niche,
which has grown signiﬁcantly due to the continuous supply of lipids from Golgi ministacks, is now fortiﬁed against premature lysis and ultimately provides a safe space for
RBs to differentiate into infectious EBs and perpetuate the infectious cycle.
DISCUSSION
Here, we have identiﬁed a virulence pathway in which the bacterial pathogen
Chlamydia trachomatis uses a single chlamydial effector to integrate ARF1 and RhoA
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FIG 5 Activation of ARF1 impairs RhoA-GTP-dependent actin scaffold formation. (A) HeLa cells were infected
with WT C. trachomatis L2 (MOI of 2) and transfected with ARF1WT-HA, ARF1Q71L-HA, or ARF1T31N-HA DNA at 4
hpi. Cells were ﬁxed at 32 hpi and labeled with anti-HA antibody (green) and phalloidin (red). Asterisks denote
inclusions. Scale bar, 20 m m. The white box indicates the magniﬁed area shown to the right of the image
(Zoom). (B) The graph depicts the average percentage of inclusions with actin scaffolds from 3 independent
experiments 6 the standard deviation. Data are normalized to cells transfected with ARF1WT-HA DNA. A
minimum of 100 inclusions was counted for each condition from 3 independent experiments. ***, P , 0.001.
(C) HeLa cells were infected with WT C. trachomatis L2 (MOI of 1) and transfected with ARF1WT-HA or ARF1Q71LHA DNA at the time of infection. The levels of RhoA-GTP were determined as described in Fig. 1C. The graph
depicts the average fold change of RhoA-GTP normalized to ARFWT-HA expressing cells from 3 independent
experiments 6 the standard deviation. **, P , 0.01.

cross talk to precisely time the formation of PTM-MT and actin scaffolds (Fig. 6). Many
other intracellular pathogens also target GTPases (29) and integrate GTPase cross talk
into their virulence systems. An example is the effector protein EspG expressed by
enteropathogenic E. coli OH157:H7, which disrupts ER-to-Golgi trafﬁcking by linking
ARF1-speciﬁc vesicular trafﬁcking events to Rab1 inactivation (30, 31). EspG also blocks
phagocytosis by interacting with ARF1 to prevent Rac1 activation and consequently the polymerization of actin at the plasma membrane (32). In contrast, Salmonella enterica co-opts
an ARF6-ARF1-Rac1 axis to drive plasma membrane rufﬂing required for entry (33). The
Chlamydia virulence pathway is most similar to that utilized by Salmonella since Chlamydia
activates rather than inhibits the ARF1-RhoA network to promote successful infection. In
this pathway, both RhoA and ARF1 elegantly ﬁne-tune their activity by generating simultaneous feedback loops. The activation of ARF1 prevents the activation of RhoA, while the
presence of RhoA downregulates ARF1 activation. While GTPases are well known to regulate each other (34–37), how RhoA and ARF1 inﬂuence the function of each other is
unknown. Furthermore, whether this process requires other bacterial factors or is an inherent property of these GTPases and their respective effector proteins is under investigation.
Since GTPases are critical components of host signaling networks, manipulating
their function or activity can have detrimental consequences for the host. In particular,
dysregulation of GTPases involved in coordinating the host cytoskeleton has been
linked to cancer hallmarks, such as uncontrolled cell proliferation, migration, and
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differentiation (38, 39). ARF1 and RhoA have been implicated in some aspects of cancer
development, including tumor cell invasion and proliferation (40–45). Given that
Chlamydia infection has been associated with an increased risk for developing cervical
and ovarian cancers (46–48), it would be interesting to determine whether the activation of the ARF1-RhoA signaling axis contributes to the potentiation of cancer development in those with a history of chronic Chlamydia infection.
As an absolute intracellular bacterium, Chlamydia must ensure the integrity of its intracellular niche to establish a successful infection. As Chlamydia replicates inside the
inclusion, this bacterial compartment matures and expands to eventually occupy most
of the host cytoplasm (49). We have previously shown that InaC KO Chlamydia displays
smaller inclusions and is replication deﬁcient (15). These defects may be due to a combination of factors. (i) They may be a consequence of reduced PTM-MT scaffold formation,
which impairs the recruitment of Golgi ministacks around the inclusion that play a role
in lipid acquisition and inclusion development (50). (ii) Premature lysis could result in the
release of Chlamydia into the cytoplasm before the cells have successfully differentiated
from RBs into infectious EBs. We show here that InaC KO inclusions lyse signiﬁcantly earlier than their WT counterparts (Fig. 3A). Since the infected cells then undergo more cell
death (Fig. 3B) due to cytoplasmic Chlamydia, the bacterium reaches an impasse. While
both possibilities likely contribute to the survival of Chlamydia, our data demonstrate
that the chlamydial effector protein InaC is critical for the protection of Chlamydia's intracellular niche and successful infection by controlling two cytoskeletal networks.
InaC is required to activate both ARF1 and RhoA, which is tightly regulated during
Chlamydia infection (Fig. 2) (15). This suggests that InaC may possess intrinsic GEF activity. However, we have shown that InaC does not exhibit GEF activity in vitro (15),
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FIG 6 Model of cytoskeletal cross talk during Chlamydia infection. Chlamydia trachomatis expresses the
inclusion membrane protein InaC on the surface of its inclusion facing the host cytosol. InaC is required
to activate the host GTPases ARF1 and RhoA on the inclusion membrane and, consequently, for the
formation of both PTM-MT and actin scaffolds, respectively. Both PTM-MT and actin scaffolds are essential
for Chlamydia development and survival. ARF1-GTP is involved in the posttranslational modiﬁcation of MT
scaffolds around the inclusion, which supports Golgi recruitment and nutrient acquisition. ARF1 activation
peaks early during infection. As RhoA begins to accumulate on the inclusion ;24 hpi, its presence locally
inhibits ARF1 activation and prevents the formation of additional PTM-MTs. Simultaneously, the presence
of ARF1-GTP prevents the activation of RhoA and the formation of actin scaffolds early during infection.
As ARF1 becomes deactivated and RhoA-GTP reaches its maximum, the formation of actin scaffolds
begins. The continual presence of RhoA prevents PTM-MT scaffolds from unnecessarily forming late
during infection. The accumulation of actin scaffolds around the inclusion ensures the maximal stability of
the inclusion membrane. Figure created with BioRender.com.

indicating that other factors likely activate ARF1 and RhoA. How these GTPases are
being inactivated and how this inactivation is coordinated are also unknown. Due to
the signiﬁcant number of ARF1 and RhoA GEFs and GTPase-activating proteins (GAPs)
(51, 52), it is challenging to postulate what speciﬁc regulators may be involved.
Nevertheless, GEFs containing GAP domains (52), or GAPs that have both ARF and
RhoA GAP domains (53), may be critical for coupling the activities of ARF1 and RhoA.
Our data demonstrate that PTM-MT and actin scaffold formation occurs with distinct kinetics and that disruption of one of these pathways impacts the other. For
example, we show that the constitutive activation of ARF1 blocks the formation of
actin scaffolds (Fig. 5). Why can't actin scaffolds form in the presence of PTM-MT scaffolds? One possibility is steric hindrance. Since PTM-MTs woven around the inclusion
possess enhanced stability and rigidity, the presence of these cytoskeletal elements
might limit access to the inclusion membrane either for actin effectors to interact with
chlamydial effectors or for the polymerization of actin itself. Additionally, PTM-MT and
actin scaffolds may share critical components for their formation. We have already
identiﬁed InaC as such a regulator; however, other host effectors may also be shared
between these two pathways. For example, host formins control the generation of
PTM-MTs and the polymerization of actin ﬁlaments (54). Thus, the activation of ARF1dependent PTM-MTs may sequester critical components away from the actin pathway
until ARF1 is inactivated, and these effectors can then participate in RhoA-dependent
actin scaffold formation. Identiﬁcation of these components will provide insight into
how Chlamydia coordinates the speciﬁc kinetics of each of these cytoskeletal scaffolds.
While the activation of ARF1 blocks actin scaffold formation, the loss of RhoA results
in the enhanced interaction between ARF1 and InaC and increased PTM-MT scaffold formation (Fig. 4). This phenotype can be reversed by the expression of RhoA in any of its
nucleotide-bound states (Fig. 4; Fig. S7). The nucleotide independence of this complementation suggests that (i) the presence of RhoA on the inclusion is sufﬁcient to downregulate ARF1 or (ii) RhoA may interact with effectors irrespective of its nucleotidebound state to shut off ARF1. Several reports have documented that RhoA and other
GTPases interact with other proteins in a nucleotide-independent manner to control
their localization and activation (55–57). Thus, not only has Chlamydia co-opted two host
GTPases to coordinate the formation of two cytoskeletal scaffolds, but it has also taken
advantage of both nucleotide-dependent and -independent functions of these GTPases.
In summary, our ﬁndings have revealed a mechanism by which Chlamydia utilizes a single effector protein to control two cytoskeletal pathways. By employing GTPase cross talk,
Chlamydia temporally regulates the assembly of PTM-MT and actin scaffolds around its inclusion to maintain its parasitic niche. Ultimately, identifying the molecular players participating
in these pathways will uncover new targets to combat Chlamydia trachomatis infection.
MATERIALS AND METHODS
Cell culture and transfections. HeLa cells (CCL-2; ATCC) and Nuclight Red HeLa cells (Essen Biosciences)
were cultured as described previously in Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing 10% fetal
bovine serum (FBS), 10 m g/ml gentamicin, and nonessential amino acids (15). Cells were transfected with
Continuum transfection reagent (Gemini Bioproducts) using 25 to 50 ng of DNA according to the manufacturer's instructions. For siRNA transfections, HeLa cells were transfected using 25 nM siRNA and DharmaFect
1 reagent (Horizon) according to the manufacturer’s instructions 48 h before infection. SmartPool ONTARGETplus human ARF1 and nontargeting control siRNA were purchased from Dharmacon (15).
Chlamydia strains. Wild-type Chlamydia trachomatis serovar L2 (LGV 434/Bu) and InaC KO L2 were
obtained from Ted Hackstadt (NIH, Rocky Mountain Laboratories) (15). C. trachomatis L2 was propagated
and density gradient puriﬁed as described preiously (58, 59). The InaC KO and InaC-FLAG C. trachomatis
L2 strains were generated previously (15, 60). InaC-FLAG-expressing InaC KO C. trachomatis L2 was produced by transforming InaC KO C. trachomatis L2 with InaC-FLAG pBomb4S-Tet encoding InaC-FLAG
under the control of a tetracycline promoter as previously described (15).
Recombinant DNA and cloning. PCR and cloning were conducted using standard procedures.
ARF1WT-HA and ARF1Q71L-HA were generated as previously described (15). ARF1T31N-HA was made by
PCR ampliﬁcation of ARF1T31N (J. Keen, Thomas Jefferson University) and ligation into pcDNA3.1(1) containing a C-terminal HA tag. myc-RhoAWT was ampliﬁed and ligated into pRK5 containing an N-terminal
myc tag. myc-RhoAG14V and myc-RhoAT31N were generated using QuikChange PCR (Agilent) according to
the manufacturer’s instructions. InaC-FLAG pBomb4S-Tet was generated by exchanging the green ﬂuorescent protein (GFP) cassette in CT813-FLAG pBomb4-Tet (15) with a spectinomycin resistance cassette.
November/December 2021 Volume 12 Issue 6 e02397-21

mbio.asm.org

13

Downloaded from https://journals.asm.org/journal/mbio on 11 January 2022 by 147.140.233.15.

®

Coordination of Actin and Microtubules by Chlamydia

Antibodies. The following primary antibodies were used: anti-HA (chicken, A190-106A; Bethyl
Laboratories), anti-actin (rabbit, A2066; Sigma), anti-myc (mouse, 9E10 clone; Juan Bonifacino, NIH), antimyc (rabbit, 2278; Cell Signaling), anti-RhoA (mouse, ARH04; Cytoskeleton), anti-RhoA (mouse, SAB1400017;
Sigma), anti-FLAG (mouse, F1804; Sigma), anti-FLAG (rabbit, 600-401-383; Rockland Immunochemical), antiARF1 (mouse, sc-53168; SCBT), anti-a-tubulin (mouse, T5168; Sigma), anti-acetylated a-tubulin (mouse,
T6793; Sigma), anti-detyrosinated a-tubulin (rabbit, 48389; Abcam), ActiStain-488 (PHDG1; Cytoskeleton),
Actistain-555 (PHDH1-A; Cytoskeleton), anti-heat shock protein 70 (HSP70) (chicken, SPC-178D; StressMarq),
anti-InaC (mouse; T. Hackstadt), anti-IncA (rabbit; T. Hackstadt), and anti-MOMP (goat, 1621; ViroStat). The
following secondary reagents were used: Hoechst dye (H1399) and goat and donkey anti-mouse, anti-goat,
anti-rabbit, and anti-chicken (IgY) IgG Alexa Fluor 488-, 555-, or 647-conjugated secondary antibodies
(Invitrogen). Donkey anti-chicken, anti-mouse, or anti-rabbit IgG and IgY horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Invitrogen.
Generation and characterization of the RhoA KO CRISPR/Cas9 cell line. Guide RNAs targeting
human RhoA was designed using the sequences available in GenBank and analyzed for their efﬁciency
and off-target effects, using the CRISPOR (61) and the Broad Institute single guide RNA (sgRNA) designer
(62) databases with default cutoffs. The optimal guide RNA was prepared by annealing primers FO1033
(59-CAC CGG AAC TAT GTG GCA GAT ATC G-39) and FO1034 (59-AAA CCG ATA TCT GCC ACA TAG TTC C39). The guide RNA was then inserted into the BsbI site of the pSpCas9(BB)-2A-GFP (PX458) vector (S.
Kim, Thomas Jefferson University) and conﬁrmed by Sanger sequencing (Genewiz). HeLa cells were then
transfected with pSpCas9(BB)-2A-GFP containing the guide RNA as well as the empty vector (no guide
RNA) as described previously (63). Individual clones were isolated by limited dilution. Successful knockout of RhoA was conﬁrmed by Western blotting. Cell division analysis using carboxyﬂuorescein succinimidyl ester (CFSE) labeling was conducted as described previously (63).
Preparation of cell lysates for Western blot analysis. Cells were washed with PBS and lysed with
ice-cold lithium dodecyl sulfate (LDS)-PAGE sample buffer (Invitrogen) containing 250 U/m l benzonase
(Accelagen), 1 m g/ml pepstatin A, 5 m g/ml leupeptin, 1 mM phenylmethylsulfonyl ﬂuoride, 10 mM sodium ﬂuoride, and 5.4 mM sodium orthovanadate for 10 min on ice. b -Mercaptoethanol was then added
to a ﬁnal concentration of 0.36 M at 95°C for 5 min, followed by centrifugation at 20,000  g at 4°C for
10 min. Protein concentrations were determined using the Pierce 660-nm protein assay reagent containing ionic detergent compatibility reagent and read at 660 nm in a SpectraMax M2 plate reader.
Western blotting. Samples were separated on 4- to 12% bis-Tris SDS-PAGE gels (Invitrogen) and
transferred to polyvinylidene diﬂuoride membranes for 1 h at 90 V and 4°C in transfer buffer (25 mM
Tris, 192 mM glycine, 10% methanol). Membranes were washed in TBS (25 mM Tris base, 150 mM NaCl
[pH 7.5]) and then dried at room temperature for 1 h. Membranes were rehydrated with methanol and
washed with TBS and TBST (TBS containing 0.1% Tween 20). Membranes were then blocked for 1 h at
room temperature with blocking buffer (3% bovine serum albumin and 0.05% sodium azide in TBST).
After blocking, membranes were incubated in primary antibody overnight at 4°C in blocking buffer.
Membranes were washed with TBST before incubation with HRP-conjugated secondary antibody for 1 h
at room temperature in 0.5% milk diluted in TBST. Membranes were then washed several times with
TBST and TBS and revealed with SuperSignal West Dura extended duration substrate (Thermo Scientiﬁc).
Membranes were imaged on a FluorChem R system (ProteinSimple). Band intensities were quantiﬁed
using AlphaView software (ProteinSimple).
Inclusion lysis analysis. Cells were infected with WT or InaC KO C. trachomatis L2 at a multiplicity of
infection (MOI) of 0.5 and ﬁxed at the indicated times. When noted, WT C. trachomatis L2-infected cells
were treated with either 0.5 m M latrunculin B or ethanol (vehicle control) in cell culture medium for 30 min
at 37°C 5 h prior to ﬁxation. Latrunculin B and ethanol were washed out with cell culture medium, and cells
were ﬁxed at the indicated times. For complementation of inclusion stability, HeLa cells were infected with
WT or InaC-FLAG-expressing InaC KO C. trachomatis L2 at an MOI of 0.5 and ﬁxed at 48 hpi. Inclusion integrity was determined by labeling inclusions with IncA and identifying discontinuity in the labeling of IncA on
the inclusion membrane. An inclusion was considered broken or lysed when one or more substantial gaps
in the incidence of IncA labeling were observed using wide-ﬁeld ﬂuorescence microscopy. Most of the broken inclusions were missing large pieces of the inclusion membrane. When inclusion integrity was less
clear, the presence of Chlamydia in the cytosol was used to identify a broken inclusion.
Immunoﬂuorescence microscopy. HeLa cells were ﬁxed with either (i) 4% paraformaldehyde in PEMS
buffer (80 mM PIPES, 5 mM EDTA, 2 mM MgCl2, 50 mM sucrose [pH 6.8]) for 15 min at room temperature or
(ii) ice-cold methanol for 10 min at room temperature. Cells were then washed in IF-G buffer (25 mM
HEPES, 150 mM NaCl, 900 nM CaCl2, 500 nM MgCl2, 100 mM glycine [pH 7.5]) for paraformaldehyde ﬁxation
or IF buffer (25 mM HEPES, 150 mM NaCl, 900 nM CaCl2, 500 nM MgCl2 [pH 7.5]) for methanol ﬁxation.
Permeabilization was performed with 0.2% Triton X-100 in IF buffer for 10 min, followed by washes with
0.1% Triton X-100 in IF buffer. Cells were then blocked for 1 h with either (i) goat serum (10% goat serum,
0.05% sodium azide, 0.1% Triton X-100 in IF buffer) or (ii) donkey serum (10% donkey serum, 0.05% sodium
azide, 0.1% Triton X-100 in IF buffer) blocking buffer. After blocking, cells were treated with the primary
antibodies diluted in the appropriate blocking buffer for 1 h at room temperature. Cells were washed with
0.1% Triton X-100 in IF buffer and subsequently incubated with Alexa Fluor-conjugated secondary antibodies and Hoechst, diluted in the appropriate blocking buffer for 1 h at room temperature. Cells were washed
0.1% Triton X-100 in IF buffer, followed by multiple washes with IF buffer, and mounted on coverslips with
ProLong glass antifade mounting medium (Invitrogen). For inclusion lysis experiments, permeabilization,
blocking, and subsequent washes were performed in 0.1% saponin instead of Triton X-100. A minimum of
100 cells per condition were observed and imaged with a 60 oil immersion lens on a Nikon TiE inverted
ﬂuorescence microscope and Elements software (Nikon). Images were processed using ImageJ (NIH).
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ARF1 and RhoA activation assays. Cells were seeded at a density of 2.9  106 cells per 150-mm tissue
culture dish 24 h before infection with the indicated strains at an effective MOI of 1. Each plate of cells was
lysed at 24 hpi (for ARF1) or 32 hpi (for RhoA) in 700 m l of 2 lysis buffer (50 mM Tris, 10 mM MgCl2, 0.5 M
NaCl, 2% Igepal [pH 7.5]) containing protease inhibitor cocktail (K1007; APExBio) and immediately clariﬁed
by centrifugation at 20,000  g for 1 min at 4°C. Lysates were rapidly frozen in liquid nitrogen and stored at
280°C. Isolation of ARF1-GTP was performed as described previously (15), using GST-GGA1 agarose and
800 m g of cell lysate diluted to 1 lysis buffer using distilled water. RhoA-GTP was isolated using a similar
protocol, except the GST-GGA1 was replaced with the GST-Rhotekin RBD agarose beads (BK036;
Cytoskeleton). The amount of active GTPase was determined by dividing the ARF1-GTP or RhoA-GTP signal
from the pulldown with the ARF1 or RhoA signal from the cell lysate (total GTPase).
Immunoprecipitation. Prior to lysis, cells were ﬁxed in 0.6% paraformaldehyde for 20 min at 4°C.
Fixed cells were quenched with multiple washes in IF-G buffer. HeLa cells were lysed in ice-cold lysis
buffer as described previously (15). Lysates were clariﬁed by centrifugation, and equal amounts of protein were incubated overnight at 4°C with an anti-FLAG or anti-myc antibody immobilized on protein G
Plus agarose beads. The beads were washed with lysis buffer and boiled at 95°C for 5 min in NuPAGE
LDS sample buffer (Invitrogen). All samples were analyzed by Western blotting.
Caspase 3/7 assay. IncuCyte HeLa Nuclight Red cells (Essen Biosciences) were seeded into 96-well
plates at a density of 7.5  103 cells per well 24 h before infection with WT C. trachomatis L2 or InaC KO
C. trachomatis L2 at an MOI of 1. The infection was synchronized by centrifugation at 1,000  g for 1 h
at room temperature. At 6 hpi, the IncuCyte caspase 3/7 green dye for apoptosis (Essen Biosciences) was
added to each well at a ﬁnal concentration of 5 m M. Wells were imaged every 2 h until 72 hpi using an
IncuCyte Zoom imaging system (Essen Biosciences). The percentage of caspase 3/7-positive cells was
calculated by dividing the number of caspase 3/7 puncta by the number of red nuclei.
Statistical analysis. A two-tailed Student's t test was employed when comparing the means from
two independent groups. GraphPad Prism 9 was used for all statistical testing and data analysis. P values
of ,0.05 were considered statistically signiﬁcant.
Data availability. The authors declare that all other relevant data supporting the ﬁndings of this study
are included in the manuscript and its supplemental ﬁles or from the corresponding author upon request.
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